Conditions: Peripheral Vascular Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 14
Healthy volunteers: no

Brief summary:
A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).

Detailed description:

Arms:
arm 1: Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks arm 2: Participants will be orally administered placebo once daily for 12 weeks.

Interventions: intervention 1: MK-0736 intervention 2: Comparator: placebo (unspecified)
Intervention descriptions: intervention 1: MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks. intervention 2: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.

Protocol document: